Amgen Inc. (AMGN) reported its fourth-quarter financial results after the closing bell on Monday.

The US biotechnology company reported total revenue of $6.846 billion (a 3% increase from the same period in 2020), just shy of the analyst forecast of $6.868 billion.

Earnings per share was reported at $4.36 (up 26% year-over-year), beating analyst forecasts of $4.04 per share.

Total revenues reported at $26 billion in 2021 – up by 2% from the previous year.

Robert A. Bradway, Chairman, and Chief Executive Officer of Amgen commented on last year’s results: “We realized strong volume growth for many of our key products during last year.”

“These products, combined with our many pipeline opportunities, position us well for long-term growth,” Bradway added.

Amgen Inc. (AMGN) chart (Weekly)

Shares of Amgen little changed at the end of the trading day on Monday, up by 0.64% at $223.49 per share. Here is how the stock has performed in the past year –

• 1 Month: -2.97%
• 3 Month: +5.75%
• Year-to-date: -0.64%
• 1 Year: -5.91%

Amgen is the 107th largest company in the World, with a total market cap of $125.90 billion.

You can trade Amgen Inc. (AMGN) and many other stocks from the NYSE, NASDAQ, HKEX, and the ASX with GO Markets as a Share CFD.

Sources: Amgen Inc., TradingView, GO Markets MT5, CompaniesMarketCap